← ANALYST RATINGS · TIPRANKS
Tilray (TLRY): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy4 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $5.05, the highest $10.00, the lowest $2.83. The average is +66.3% from the last price of $3.04.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $4.00 → $3.00−25.0% | Hold | −1.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −1.3% | Upgrade | 15.10.26on TipRanks 06:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −1.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Kenric Tyghe★★★★★★★★★★#1473 · hits 55% · avg +15.5% | Canaccord Genuity | $4.50 → $4.00−11.1% | Hold | +31.6% | Reiterated | 09.10.26on TipRanks Oct 12 05:30 | −2.0%next day −5.0% · 5 days −12.2% | ↗ |
| Derek Lessard★★★★★★★★★★#9005 · hits 54% · avg −0.1% | TD Cowen | $4.50 | Buy | +48.0% | Assigned | 09.10.26on TipRanks 09:30 | −2.0%next day −5.0% · 5 days −12.2% | ↗ |
| Frederico Gomes★★★★★★★★★★#10704 · hits 49% · avg −3.9% | ATB Cormark Capital Markets | $6.00 → $5.00−16.7% | Hold | +64.5% | Reiterated | 09.10.26on TipRanks 08:10 | −2.0%next day −5.0% · 5 days −12.2% | ↗ |
| Bill Kirk★★★★★★★★★★#12248 · hits 38% · avg −7.9% | Roth MKM | $10.00 | Buy | +228.9% | Reiterated | 06.10.26on TipRanks 09:15 | +1.1%next day −1.5% · 5 days −13.4% | ↗ |
| Aaron Grey★★★★★★★★★★#11931 · hits 35% · avg −6.2% | Alliance Global Partners | $5.00 → $4.00−20.0% | Hold | +31.6% | Reiterated | 05.10.26on TipRanks 08:50 | +2.4%next day +1.1% · 5 days −10.1% | ↗ |
| Neal Gilmer★★★★★★★★★★#9727 · hits 43% · avg −0.7% | Haywood | $3.53 → $2.83−20.0% | Hold | −7.0% | Reiterated | 02.10.26on TipRanks 07:30 | +0.4%next day +2.4% · 5 days −3.1% | ↗ |
| Unknown Analyst | Bernstein | $10.00 → $6.50−35.0% | Hold | +113.8% | Reiterated | 25.06.26on TipRanks Jun 30 21:01 | −3.0%next day +4.8% · 5 days +2.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Tilray
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 02.10.26: target $4.70 at a price of $3.57 (+31.7%); now: $5.05 at $3.04 (+66.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 1 |
| Buy | 1 | 0 | 2 | 2 | 2 | 2 |
| Hold | 7 | 5 | 4 | 3 | 3 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.01.27 (Q2 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.16 (from $-0.21 to $-0.06). Last quarter: $-0.32.
Sales
Next quarter’s sales estimate — $265M (from $246M to $272M). Last quarter: $257M.
Best top-analyst consensus in the sector · Healthcare
About Tilray
- CEO: Irwin David Simon
- Employees: 3,595
- 265 Talbot Street West, Leamington, ON, N8H 5L4, CA
- www.tilray.com
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
Data from the stock’s TipRanks forecast page, read 51 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗